ReviewInternational journal of hematology2019
HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide.
Review in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Age-related differences in donor selection priorities for allogeneic hematopoietic transplantation.Haematologica · 2026Article
- Redefining GVHD Prophylaxis: The Expanding Horizon of Posttransplant Cyclophosphamide.Advances in experimental medicine and biology · 2026Review
- Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies.Yonago acta medica · 2025Review
- A case of late-onset sinusoidal obstruction syndrome diagnosed histologically before meeting diagnostic criteria.International journal of hematology · 2025Article
- Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.Annals of hematology · 2024Review
- Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients.Annals of hematology · 2024Article
- Donor's age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience.Annals of hematology · 2024Article
- Third HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide for relapsed acute leukemia.Bone marrow transplantation · 2023Article
- A single-center experience of haploidentical stem cell transplantation in hematological malignancies.Turkish journal of medical sciences · 2023Article
- Clinical characteristics, drug resistance and death risk factors of Burkholderia cepacia infection in hematopoietic stem cell transplant patients.BMC infectious diseases · 2022Article
- Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences.Journal of clinical medicine · 2021Review
- Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients.Nature communications · 2021Article
- Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.Frontiers in immunology · 2021Review
- Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody.Blood cell therapy · 2020Article
- Resolution of bone, cutaneous, and muscular involvement after haploidentical hematopoietic stem cell transplantation followed by post-transplant cyclophosphamide in adult T-cell leukemia/lymphoma.Clinical case reports · 2020Article
- Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives.International journal of molecular sciences · 2020Review
- Donor single nucleotide polymorphism in ACAT1 affects the incidence of graft-versus-host disease after bone marrow transplantation.International journal of hematology · 2020Article
- Guest Editorial: Are "alternative" stem cell sources still alternative in the new era?International journal of hematology · 2019Article
- The Evolution of T Cell Depleted Haploidentical Transplantation.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide has spread rapidly worldwide. This strategy was initially developed in the setting of bone marrow transplantation following nonmyeloablative conditioning. Recently, peripheral blood stem cell grafts and/or myeloablative conditioning regimen have been widely used. In Japan, prospective, multicenter, phase II studies have been conducted by the Japan Study Group for Cell Therapy and Transplantation to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using posttransplant cyclophosphamide (PTCy-haploPBSCT). In the first such study (JSCT Haplo 13 study), we demonstrated that PTCy-haploPBSCT after busulfan-based reduced-intensity conditioning (RIC) enables stable donor engraftment and low incidences of both acute and chronic graft-versus-host disease (GVHD). In the second (JSCT Haplo 14 study), we showed that both myeloablative conditioning (MAC) and RIC are valid options for PTCy-haploPBSCT. Emerging evidence, including our findings, suggests that donor type (HLA-haploidentical donor versus HLA-matched related or unrelated donor) may no longer be a significant predictor of transplant outcome.
Indexed as
Identifiers
31104211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.